Francesca CONRADIE to Antitubercular Agents
This is a "connection" page, showing publications Francesca CONRADIE has written about Antitubercular Agents.
Connection Strength
4,072
-
Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis. N Engl J Med. 2022 09 01; 387(9):810-823.
Score: 0,652
-
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. N Engl J Med. 2020 03 05; 382(10):893-902.
Score: 0,548
-
Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study. Lancet Respir Med. 2018 09; 6(9):699-706.
Score: 0,489
-
Patient and provider costs of the new BPaL regimen for drug-resistant tuberculosis treatment in South Africa: A cost-effectiveness analysis. PLoS One. 2024; 19(10):e0309034.
Score: 0,189
-
Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trial. Lancet Respir Med. 2024 Dec; 12(12):975-987.
Score: 0,188
-
Target regimen profiles for tuberculosis treatment. Bull World Health Organ. 2024 Aug 01; 102(8):600-607.
Score: 0,184
-
Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial. Lancet Infect Dis. 2024 Sep; 24(9):1003-1014.
Score: 0,183
-
QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial. Lancet Infect Dis. 2021 07; 21(7):975-983.
Score: 0,146
-
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial. Lancet Respir Med. 2019 12; 7(12):1048-1058.
Score: 0,134
-
A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis. N Engl J Med. 2019 03 28; 380(13):1201-1213.
Score: 0,128
-
High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen. Eur Respir J. 2018 12; 52(6).
Score: 0,126
-
Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis. Appl Health Econ Health Policy. 2018 Feb; 16(1):43-54.
Score: 0,119
-
Persistently high early mortality despite rapid diagnostics for drug-resistant tuberculosis cases in South Africa. Int J Tuberc Lung Dis. 2017 10 01; 21(10):1106-1111.
Score: 0,116
-
A combination of baseline plasma immune markers can predict therapeutic response in multidrug resistant tuberculosis. PLoS One. 2017; 12(5):e0176660.
Score: 0,113
-
Turning the tide against tuberculosis. Int J Infect Dis. 2017 Mar; 56:6-9.
Score: 0,111
-
Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB. J Antimicrob Chemother. 2016 Apr; 71(4):1037-40.
Score: 0,103
-
Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. Eur Respir J. 2016 Feb; 47(2):564-74.
Score: 0,102
-
Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy? Antivir Ther. 2011; 16(4):527-34.
Score: 0,073
-
Development and validation of an LC-MS/MS multiplex assay for the quantification of bedaquiline, n-desmethyl bedaquiline, linezolid, levofloxacin, and clofazimine in dried blood spots. J Chromatogr B Analyt Technol Biomed Life Sci. 2025 Feb 01; 1252:124470.
Score: 0,048
-
Levofloxacin Preventive Treatment in Children Exposed to MDR Tuberculosis. N Engl J Med. 2024 Dec 19; 391(24):2315-2326.
Score: 0,048
-
Risk factors for and timing of presumptive recurrent TB. Int J Tuberc Lung Dis. 2024 Nov 01; 28(11):527-533.
Score: 0,047
-
Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement. Lancet Infect Dis. 2023 04; 23(4):e122-e137.
Score: 0,042
-
Proposed Linezolid Dosing Strategies to Minimize Adverse Events for Treatment of Extensively Drug-Resistant Tuberculosis. Clin Infect Dis. 2022 May 30; 74(10):1736-1747.
Score: 0,040
-
Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines. BMJ Open. 2021 12 03; 11(12):e051521.
Score: 0,039
-
Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study. Lancet Infect Dis. 2022 04; 22(4):496-506.
Score: 0,039
-
Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosis. Eur Respir J. 2020 03; 55(3).
Score: 0,034
-
Frequency of Circulating CD4+Ki67+HLA-DR- T Regulatory Cells Prior to Treatment for Multidrug Resistant Tuberculosis Can Differentiate the Severity of Disease and Predict Time to Culture Conversion. Front Immunol. 2018; 9:2438.
Score: 0,031